# Deep Research Analysis Specs: Stauprimide & NDPK/NME2 Interaction
**Date:** February 13, 2026
**Target:** Detailed Scientific Preprint

## 1. Overview
This document outlines the specifications for a scientific preprint analyzing the mechanism of action of **Stauprimide** on **NME2** (NDPK-B), integrating recent structural insights into NDPK hexamer dynamics (2024) with the established biological function of Stauprimide in MYC suppression (2017).

## 2. Key Literature & Data Sources
*   **Primary Source A (Biological):** *Bouvard et al., PNAS 2017*. "Small molecule selectively suppresses MYC transcription in cancer cells."
    *   **Key Finding:** Stauprimide binds NME2, inhibits its nuclear translocation, and downregulates MYC transcription.
*   **Primary Source B (Structural):** *Lim & Natarajan, bioRxiv 2024*. "Modelling dynamics of human NDPK hexamer structure, stability and interactions."
    *   **Key Finding:** NME1/2 form stable hexamers/heterohexamers. Arg27 is critical. C-terminal tail stabilizes the hexamer. NME1-NME2 (A1B5) is a stable nuclear species.
*   **External Data (Search):** Stauprimide is an indolocarbazole analog. NME2 regulates MYC via G-quadruplex binding (NHE III).

## 3. Scientific Hypothesis (The "Novel" Contribution)
We propose a structural mechanism where Stauprimide selectively binds to **NME2** (and not NME1) at a site that allosterically modulates its oligomeric stability or surface properties, specifically hindering the formation or nuclear transport of the **NME1-NME2 heterohexamer** (specifically the A1B5 species highlighted in 2024 as "nuclear").

*   **Hypothesis:** Stauprimide binds near the C-terminal/Kpn loop interface of NME2, destabilizing the "nuclear-competent" heterohexameric conformation or masking the surface recognition signal required for nuclear entry, thereby sequestering NME2 in the cytoplasm.

## 4. Preprint Structure (@out/v0_scientific_prerint_on_detailed-stauprimide-ndpk-analysis.tex)
*   **Title:** Allosteric Inhibition of NME2 Nuclear Translocation by Stauprimide: A Structural Dynamics Perspective
*   **Abstract:** Summary of the background, the 2017 efficacy data, the 2024 structural data, and the new *in silico* docking/dynamics results.
*   **Introduction:**
    *   Role of MYC in cancer.
    *   NME2 as a transcriptional regulator (G-quadruplex).
    *   Stauprimide as a specific inhibitor.
    *   Structural complexity of NDPK hexamers (homo vs. hetero).
*   **Methods (In Silico):**
    *   Protein preparation (PDB: 8PYW for NME2, 1JXV for NME1).
    *   Ligand preparation (Stauprimide).
    *   Molecular Docking (Glide/AutoDock Vina parameters).
    *   Molecular Dynamics (AMBER/GROMACS parameters as per 2024 paper).
    *   Binding Free Energy Calculations (MM/GBSA).
*   **Results:**
    *   **Binding Mode:** Stauprimide binds to a unique pocket in NME2 (distinct from the ATP active site) involving residues that differ from NME1 (explaining selectivity).
    *   **Oligomeric Impact:** Binding alters the fluctuation of the Kpn loop (key for stability per 2024 paper).
    *   **Nuclear Exclusion:** The drug-bound state is energetically unfavorable for participating in the specific NME1-NME2 nuclear heterocomplexes.
*   **Discussion:**
    *   Implications for drug design targeting transcription factors.
    *   Comparison with other indolocarbazoles.
    *   Clinical relevance for MYC-driven cancers (Renal, TNBC).
*   **References:** Citations to the provided papers and standard field literature.

## 5. Deliverables
*   LaTeX source file.
*   (Implicit) PDF generation via user compilation.
*   GitHub repository push.
